Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Mixed alignment with the provided label text: several safety/pharmacology concepts are consistent, but multiple claims are unsupported/over-specified (e.g., obesity indication; hepatic glucose production; 'common' and 'especially when first starting' timing; diarrhea attribution to volume-depletion section; contraindications framed broadly/imprecisely). Several items also lack adequate label support due to missing or non-matching section citations.
Category Scores
Accurate Statements
Ozempic is a GLP-1 receptor agonist.
12.1 Mechanism of Action
Ozempic is used to treat type 2 diabetes.
1 INDICATIONS AND USAGE (adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus)
Ozempic stimulates the release of insulin.
12.1 Mechanism of Action (stimulates insulin secretion; glucose-dependent)
Nausea and vomiting with Ozempic can be severe in some cases.
5.2 Acute Pancreatitis; 5.6 Acute Kidney Injury Due to Volume Depletion; 5.7 Severe Gastrointestinal Adverse Reactions
Ozempic-associated diarrhea can lead to dehydration.
5.6 Acute Kidney Injury Due to Volume Depletion (GI reactions leading to dehydration such as nausea, vomiting, or diarrhea)
Ozempic has been linked to an increased risk of pancreatitis.
5.2 Acute Pancreatitis
Ozempic use is associated with a potential increased risk of thyroid C-cell tumors.
WARNING: RISK OF THYROID C-CELL TUMORS
Ozempic can cause allergic reactions, including anaphylaxis.
5.8 Hypersensitivity Reactions (anaphylaxis, angioedema reported)
Ozempic can increase the risk of acute kidney injury.
5.6 Acute Kidney Injury Due to Volume Depletion
Ozempic can increase the risk of hypoglycemia.
5.5 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
The risk of hypoglycemia with Ozempic is higher when used in combination with other diabetes medications (supported when specified as insulin secretagogues such as sulfonylureas or insulin).
5.5 and 7.1 (increased risk with insulin secretagogue (e.g., sulfonylurea) or insulin; consider dose reduction)
Ozempic use is associated with a potential increased risk of gallbladder disease.
5.9 Acute Gallbladder Disease
Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2 (thyroid C-cell tumor related contraindication is directionally aligned).
WARNING: RISK OF THYROID C-CELL TUMORS; 4 CONTRAINDICATIONS (personal/family history of MTC or MEN 2)
Unsupported Statements
Ozempic is used to treat obesity.
Label provided (1 INDICATIONS AND USAGE) includes type 2 diabetes and cardiovascular/kidney risk reduction in type 2 diabetes; obesity indication is not present in the supplied label sections.
Ozempic reduces the production of glucose in the liver.
No supplied label section states 'reduces the production of glucose in the liver' for semaglutide; 12.1 only describes glucose lowering via insulin/glucagon secretion (glucose-dependent) and a minor delay in gastric emptying.
Common side effects include nausea and vomiting, especially when first starting Ozempic.
Supplied label text in 5.7 and 5.6 discusses severe GI adverse reactions and not being 'common' or specifically 'especially when first starting' as stated.
Nausea and vomiting with Ozempic is usually mild and temporary.
No supplied label text supports 'usually mild and temporary' characterization; only severity-related and observational statements are provided.
Ozempic can cause diarrhea.
The provided citations do not clearly establish diarrhea as a standalone adverse reaction category; supplied label text ties diarrhea to GI reactions leading to dehydration/AKI (5.6) but does not explicitly support diarrhea as a general adverse reaction claim in the way presented.
Ozempic can cause injection site reactions (including redness, swelling, or itching).
No supplied label section mentions injection site reactions.
Ozempic can cause headache; headaches are usually mild and temporary.
No supplied label section mentions headache or severity/temporariness.
Some patients may experience depression or anxiety while taking Ozempic.
No supplied label section mentions depression or anxiety.
Ozempic is contraindicated in patients with a history of pancreatitis.
The provided contraindications section (4 CONTRAINDICATIONS) lists MTC/MEN 2 and serious hypersensitivity only; 'history of pancreatitis' is not shown as a contraindication in the supplied text.
Ozempic is contraindicated in patients with severe gastrointestinal disease.
The provided contraindications section (4 CONTRAINDICATIONS) does not list 'severe gastrointestinal disease' as a contraindication; only severe gastroparesis is addressed as 'not recommended' (5.7).
The risk of acute kidney injury with Ozempic is especially higher in patients with pre-existing kidney disease.
5.6 calls for monitoring in patients reporting adverse reactions leading to volume depletion, but the supplied text does not explicitly state risk is 'especially higher' with pre-existing kidney disease.
Contradictions
Important Omissions
Dose selection, titration, missed-dose guidance, and any dosage adjustments (including renal function dosing considerations).
Importance:
Moderate
Administration-specific instructions for Ozempic (e.g., subcutaneous administration details, handling/injection guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-critical items are partially supported but include notable imprecision/unsupported contraindication claims (e.g., 'history of pancreatitis' and 'severe gastrointestinal disease' as contraindications) and unsupported broad adverse effect generalizations (timing/commonness, diarrhea as a standalone AE). These issues could mislead risk interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple unsupported or imprecisely framed label claims (obesity indication; liver glucose production; 'common' and 'especially when first starting' timing; contraindication framing for pancreatitis history and severe GI disease; diarrhea/headache/injection-site/depression-anxiety not supported by supplied label text).
Suggested Improvement
Restrict claims to the supplied label text: use only label-listed indications (type 2 diabetes; CV and CKD risk reduction), avoid mechanistic statements not present (e.g., hepatic glucose production), qualify GI adverse reactions using supplied wording (severe GI reactions and not recommended in severe gastroparesis), and ensure contraindications match the provided contraindications section (MTC/MEN 2; serious hypersensitivity to semaglutide/excipients).